Medirom Healthcare Technologies Inc

Medirom Healthcare Technologies Inc(MRM)股票分析

$0.284

-0.004 (-1.46%)收盘时

Loading chart…
最高
0.300
开盘
0.300
成交量加权均价
0.29
成交量
13.98K
市值
18.55M
最低
0.280
成交额
4.03K
企业价值/息税折旧摊销前利润(TTM)
0.00

Medirom Healthcare Technologies Inc is a Japan-based holistic health services provider. The Company is a franchiser and operator of healthcare salons across Japan and is a preferred platform partner for large consumer brands, healthcare service providers and government entities. The Company mainly operates in two business segments. The Relaxation Salon Segment is engaged in the development of relaxation studios nationwide, centered on Re.Ra.Ku for the purpose of health management services. The Digital Preventative Healthcare Segment is involved in the sampling business, which includes brand promotion and consumer analysis for third party brands of corporate clients, government-sponsored specific health guidance program, utilizing internally-developed on-demand health monitoring smartphone application Lav, as well as MOTHER Tracker for fitness applications, and preventative healthcare services utilizing digital application and devices.

AI 分析 of Medirom Healthcare Technologies Inc (MRM)

卖出

Medirom Healthcare Technologies Inc (MRM) is not a good buy right now due to its extremely low RSI of 12.99, indicating it is oversold, and a staggering year-to-date change of -85.49%. The company's gross margin has improved to 99.65% in the last quarter, but the overall financial health is concerning with a debt-to-equity ratio of 174.83% and a current ratio of only 1.75, suggesting liquidity issues. The main risk is the significant decline in stock price, which has dropped 48.57% over the last 20 days, indicating a lack of investor confidence and potential further declines.

估值指标

Medirom Healthcare Technologies Inc(MRM)当前预期市盈率为 0.00,5 年平均预期市盈率为 0.00。

预期市盈率

严重低估
5 年均值 P/E
0.00
当前P/E
0.00
高估
0.00
低估
0.00

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
2.75
当前EV/EBITDA
0.00
高估
7.92
低估
-2.42

预期市销率

合理
5 年均值 P/S
0.04
当前P/S
0.00
高估
0.14
低估
-0.05

Alphio AI 对 MRM 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%MRM

$1.40

情景价格

基

基准

基准 · 50%MRM

$1.32

情景价格

悲

悲观

悲观 · 25%MRM

$1.07

情景价格

事件时间线

2026-02-27 (ET)

08:10:00

Medirom Healthcare Signs Agreement with Tools for Humanity, Projects $39 Million Income Over Two Years

2025-12-29 (ET)

08:30:00

MEDIROM Collaborates with World Foundation to Deploy Proof of Human Technology in Japan

2025-12-26 (ET)

18:00:00

Medirom Healthcare Partners with World Foundation to Deploy Proof of Human Technology

2025-10-29 (ET)

10:25:23

Medirom Healthcare to Introduce New Treasury Strategy Utilizing Cryptocurrency

2025-10-28 (ET)

08:36:02

Medirom Healthcare reports that more than 10,000 individuals have obtained World IDs at various locations.

资讯

MRM 常见问题 —— 由 Alphio AI 解答

Medirom Healthcare Technologies Inc is a Japan-based holistic health services provider. The Company is a franchiser and operator of healthcare salons across Japan and is a preferred platform partner for large consumer brands, healthcare service providers and government entities. The Company mainly operates in two business segments. The Relaxation Salon Segment is engaged in the development of relaxation studios nationwide, centered on Re.Ra.Ku for the purpose of health management services. The Digital Preventative Healthcare Segment is involved in the sampling business, which includes brand promotion and consumer analysis for third party brands of corporate clients, government-sponsored specific health guidance program, utilizing internally-developed on-demand health monitoring smartphone application Lav, as well as MOTHER Tracker for fitness applications, and preventative healthcare services utilizing digital application and devices. It operates in the Consumer Non-Cyclicals sector.

Medirom Healthcare Technologies Inc (MRM) is not a good buy right now due to its extremely low RSI of 12.99, indicating it is oversold, and a staggering year-to-date change of -85.49%. The company's gross margin has improved to 99.65% in the last quarter, but the overall financial health is concerning with a debt-to-equity ratio of 174.83% and a current ratio of only 1.75, suggesting liquidity issues. The main risk is the significant decline in stock price, which has dropped 48.57% over the last 20 days, indicating a lack of investor confidence and potential further declines.

暂无帖子

注册或登录后参与讨论

相关文章

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易